Samsung Biologics, a biotech arm of South Korea's Samsung Group, said on Thursday it plans to spin off its biosimilar ...

In this week’s edition of InnovationRx, we look at how Hinge Health’s successful IPO may be a trendsetter, Indian billionaire ...

Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to ...

This designation is meaningful as it signifies our continued commitment to making biosimilars more accessible. Both biosimilars and interchangeable biosimilars are highly similar and have no ...

Costs for the average person increased by 6.7% to $7,871 in 2025 led by a 9.7% hike in pharmacy expenses and an 8.5% rise in ...

US FDA approves Bio-Thera Solutions & Hikma Pharma’s Starjemza injection, a biosimilar referencing Stelara injection: Guangzhou Wednesday, May 28, 2025, 17:00 Hrs [IST] Bio-Ther ...

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that members of its executive management team will ...

Bernstein’s 41st Annual Strategic Decisions Conference Call May 28, 2025 9:00 AM ETCompany ParticipantsJoaquin Duato ...

Fast Track is an FDA process designed to facilitate development and expedite review of drugs to treat serious conditions and ...

Molbreevi – a new inhaled formulation of the well-established and off-patent white blood cell stimulator molgramostim – is ...

The FDA has expanded the interchangeable designation for Yuflyma (adalimumab-aaty), a biosimilar to Humira, to include all presentations.